Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Nat Commun ; 13(1): 2921, 2022 05 25.
Article in English | MEDLINE | ID: mdl-35614127

ABSTRACT

Human coronavirus OC43 is a globally circulating common cold virus sustained by recurrent reinfections. How it persists in the population and defies existing herd immunity is unknown. Here we focus on viral glycoprotein S, the target for neutralizing antibodies, and provide an in-depth analysis of its antigenic structure. Neutralizing antibodies are directed to the sialoglycan-receptor binding site in S1A domain, but, remarkably, also to S1B. The latter block infection yet do not prevent sialoglycan binding. While two distinct neutralizing S1B epitopes are readily accessible in the prefusion S trimer, other sites are occluded such that their accessibility must be subject to conformational changes in S during cell-entry. While non-neutralizing antibodies were broadly reactive against a collection of natural OC43 variants, neutralizing antibodies generally displayed restricted binding breadth. Our data provide a structure-based understanding of protective immunity and adaptive evolution for this endemic coronavirus which emerged in humans long before SARS-CoV-2.


Subject(s)
COVID-19 , Coronavirus OC43, Human , Antibodies, Monoclonal , Antibodies, Neutralizing , Antibodies, Viral , Coronavirus OC43, Human/metabolism , Epitopes , Humans , SARS-CoV-2 , Spike Glycoprotein, Coronavirus
2.
Med Monatsschr Pharm ; 39(10): 421-6, 2016 Oct.
Article in German | MEDLINE | ID: mdl-29979537

ABSTRACT

The treatment of elderly multimorbid patients according to clinical guidelines often results in polypharmacy. An individual risk assessment is required to consider the possibility of deprescribing especially potentially inappropriate medication in the elderly. This exemplary case report describes a medication review of a patient with multiple chronic cardiovascular diseases taking into account the impact on renal function.


Subject(s)
Carbazoles/therapeutic use , Heart Failure/drug therapy , Hypertension/drug therapy , Kidney Failure, Chronic/chemically induced , Propanolamines/therapeutic use , Ramipril/therapeutic use , Spironolactone/therapeutic use , Aged, 80 and over , Atrial Fibrillation/drug therapy , Carbazoles/adverse effects , Carvedilol , Diclofenac/adverse effects , Diclofenac/therapeutic use , Digoxin/therapeutic use , Drug Interactions , Drug Therapy, Combination , Female , Humans , Kidney Failure, Chronic/prevention & control , Myocardial Infarction/drug therapy , Potassium/blood , Potentially Inappropriate Medication List , Propanolamines/adverse effects , Ramipril/adverse effects , Risk Factors , Spironolactone/adverse effects
3.
Berl Munch Tierarztl Wochenschr ; 123(11-12): 519-21, 516-8, 2010.
Article in English, German | MEDLINE | ID: mdl-21141283

ABSTRACT

Control of IBR and BVD should be possible in Europe. Effective vaccines and reliable tools for monitoring are available. Systematic approach and strict implementation of control measures are essential. Voluntary or mandatory programs are ongoing on regional or national level in a lot of countries. Successful programs put pressure on surrounding regions/countries to initiate control program as well.


Subject(s)
Bovine Virus Diarrhea-Mucosal Disease/prevention & control , Infectious Bovine Rhinotracheitis/prevention & control , Animals , Bovine Virus Diarrhea-Mucosal Disease/epidemiology , Bovine Virus Diarrhea-Mucosal Disease/immunology , Cattle , Europe/epidemiology , Infectious Bovine Rhinotracheitis/epidemiology , Infectious Bovine Rhinotracheitis/immunology , Viral Vaccines/therapeutic use
4.
Vet Microbiol ; 125(1-2): 49-58, 2007 Nov 15.
Article in English | MEDLINE | ID: mdl-17601689

ABSTRACT

The objective of the study was to determine the diagnostic performance of the Pourquier ELISA for detection of antibodies against Mycobacterium avium subsp. paratuberculosis (Map) in individual milk samples and in bulk milk samples. For individual milk samples the specificity of the Pourquier ELISA was estimated by testing a panel of individual milk samples from certified Map-free herds. The relative sensitivity of the assay in individual milk samples and agreement of the results with those of serum samples was estimated by testing panels of paired serum-milk samples from seropositive cattle, whole-herd investigations, and moderate or heavy shedders. The specificity of the ELISA for individual milk samples was still 99.8% at a cut-off of 20% sample to positive (S/P) value, clearly lower than the cut-off defined by the manufacturer (30% S/P). The relative sensitivity for individual milk samples as compared with positive serum samples was 87% for a cut-off of 20% S/P, and 80% for a cut-off of 30% S/P. The sensitivity of this ELISA for detection of high shedders was >90% both for individual milk and serum samples, also agreement was very good (kappa=0.91 for all paired samples). The specificity of the Pourquier ELISA in bulk milk samples was investigated by testing bulk milk samples from certified Map-free herds. Feasibility of bulk milk testing was investigated by titrating ELISA positive individual milk samples in negative milk. In addition, 383 bulk milk samples from herds with a known within-herd seroprevalence were tested. The specificity of the ELISA for bulk milk samples was 100% at a cut-off of 12.5% S/P. At the cut-off recommended by the manufacturer (30% S/P) performance of the bulk milk ELISA related to herd status (> or =2 seropositive cows) was rather poor, corresponding with a sensitivity of 24% and a specificity of 99% relative to serology. However, at the revised cut-off for bulk milk of 12.5% S/P and a within-herd seroprevalence of > or =3%, sensitivity and specificity relative to serology were 85% and 96%, respectively. Given the current herd-level seroprevalence in The Netherlands, these test characteristics corresponded with positive and negative predictive values for bulk milk of 67% and 94%, respectively. In conclusion, the diagnostic performance of the Pourquier ELISA for individual milk samples creates opportunities for a cheaper and more feasible testing scheme, while the diagnostic performance for bulk milk samples warrants further consideration.


Subject(s)
Cattle Diseases/microbiology , Enzyme-Linked Immunosorbent Assay/veterinary , Milk/microbiology , Mycobacterium avium subsp. paratuberculosis/isolation & purification , Paratuberculosis/microbiology , Animals , Antibodies, Bacterial/analysis , Cattle , Cattle Diseases/diagnosis , Enzyme-Linked Immunosorbent Assay/methods , Female , Netherlands , Paratuberculosis/blood , Paratuberculosis/diagnosis , Predictive Value of Tests , ROC Curve , Sensitivity and Specificity , Seroepidemiologic Studies
5.
Vaccine ; 24(14): 2550-9, 2006 Mar 24.
Article in English | MEDLINE | ID: mdl-16417949

ABSTRACT

Paratuberculosis is a chronic granulomatous inflammation of the small intestine of cattle and other ruminants, caused by infection with Mycobacterium avium ssp. paratuberculosis (MAP). The disease can be found in ruminant herds worldwide, causing substantial economic losses at farm level due to premature culling and production losses. In previous studies, it has been shown that immune responses to recombinant MAP Hsp70 proteins were predominantly cell mediated. As protective immunity to the intracellular mycobacterial pathogens is thought to be cell-mediated in origin, we have studied the use of a recombinant MAP Hsp70 as a subunit vaccine in cattle experimentally infected with MAP. The results of the current study demonstrate that recombinant MAP Hsp70 can be successfully used as a subunit vaccine against bovine paratuberculosis, significantly reducing shedding of bacteria in feces during the first 2 years following experimental infection.


Subject(s)
HSP70 Heat-Shock Proteins/administration & dosage , Paratuberculosis/prevention & control , Vaccines, Subunit/administration & dosage , Animals , Antigens, Bacterial/immunology , Cattle , Feces/microbiology , HSP70 Heat-Shock Proteins/immunology , Mycobacterium avium subsp. paratuberculosis/immunology , Mycobacterium avium subsp. paratuberculosis/metabolism , Paratuberculosis/immunology , Vaccines, Subunit/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...